Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNA001 vs thyroid hormone withdrawal for remnant ablation in differentiated thyroid cancer
CTR20192559Phase 3Completed
- Sponsor
- Suzhou Zhihui Biopharmaceutical Technology
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of thyrotropin alfa in well-differentiated thyroid cancer (WDTC), sponsored by Suzhou Zhihui Biopharmaceutical Technology. Started Dec 2019; status: completed.
02
Drugs
thyrotropin alfa
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20192559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192559.